<p>Drs. Nate Pennell, Mary Pinder, and Jack West discuss an encouraging study of dabrafenib, a BRAF inhibitor, for the limited number of NSCLC patients with a BRAF V600E mutation.</p>

Drs. Nate Pennell, Mary Pinder, and Jack West discuss an encouraging study of dabrafenib, a BRAF inhibitor, for the limited number of NSCLC patients with a BRAF V600E mutation.

Could BRAF be a new target in NSCLC?

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

Share Could BRAF be a new target in NSCLC?

Sign up to save your podcasts

Could BRAF be a new target in NSCLC?

Could BRAF be a new target in NSCLC?

More shows like GRACEcast Cancer 101 Audio

GRACEcast Head and Neck Cancer Audio

GRACEcast Lung Cancer Video

GRACEcast Radiation Oncology Audio

GRACEcast Radiation Oncology Video

GRACEcast Pancreatic Cancer Audio

GRACEcast Pancreatic Cancer Video

GRACEcast Bladder Cancer Video

GRACEcast Head and Neck Cancer Video NEW

GRACEcast Cancer 101 Video